Valion Bio (VBIO) Change in Account Payables (2021 - 2025)
Valion Bio (VBIO) posted Change in Account Payables of -$201000.0 for Q4 2025, down 187.01% on a QoQ basis from $231000.0 in Q3 2025, and up 3.37% year-over-year from -$194455.8 in Q4 2024.
Powered by 
Analysis
Valion Bio (VBIO) Change in Account Payables (2021 - 2025) Analysis & Trends
Valion Bio has reported Change in Account Payables for 5 years, with the latest figure at -$201000.0 in Q4 2025.
- On a quarterly basis, Change in Account Payables rose 3.37% year-over-year to -$201000.0 in Q4 2025; TTM through Dec 2025 was $139000.0, a 123.64% increase from a year earlier, with the FY2025 full-year figure at $139000.0, up 123.64% from the prior year.
- Change in Account Payables was -$201000.0 for Q4 2025 at Valion Bio, down from $231000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $1.3 million in Q2 2022, with the low at -$510000.0 in Q4 2021.
- Average Change in Account Payables over 5 years is -$5300.0, with a median of -$164500.0 recorded in 2022.
- The sharpest annual moves came in 2024 and 2025: Change in Account Payables sank 377.33% in 2024, then soared 304.42% in 2025.
- Over 5 years, Change in Account Payables stood at -$510000.0 in 2021, then jumped by 45.29% to -$279000.0 in 2022, then jumped by 126.88% to $75000.0 in 2023, then tumbled by 377.33% to -$208000.0 in 2024, then grew by 3.37% to -$201000.0 in 2025.
- The last three Change in Account Payables figures came in at -$201000.0 (Q4 2025), $231000.0 (Q3 2025), and -$204000.0 (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | -70.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 18.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | -66.70 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -8.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 7.11 Mn |
| 10 | Valion Bio | 298,792.01 | -1.90 Mn | -45,000.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -201,000.00 |
| Sep 30, 2025 | 231,000.00 |
| Jun 30, 2025 | -204,000.00 |
| Mar 31, 2025 | 313,000.00 |
| Dec 31, 2024 | -208,000.00 |
| Sep 30, 2024 | -113,000.00 |
| Jun 30, 2024 | -101,000.00 |
| Mar 31, 2024 | -166,000.00 |
| Dec 31, 2023 | 75,000.00 |
| Sep 30, 2023 | -193,000.00 |
| Jun 30, 2023 | -263,000.00 |
| Mar 31, 2023 | -229,000.00 |
| Dec 31, 2022 | -279,000.00 |
| Sep 30, 2022 | -313,000.00 |
| Jun 30, 2022 | 1.29 Mn |
| Mar 31, 2022 | -163,000.00 |
| Dec 31, 2021 | -510,000.00 |
| Sep 30, 2021 | 115,000.00 |
| Jun 30, 2021 | 519,000.00 |
| Mar 31, 2021 | 295,000.00 |